$ZGNX...Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Zogenix Inc. (NASDAQ: ZGNX) is a California-based pharmaceutical company that develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company's two main products include Zohydro (a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain) and Relday (an injectable formulation of risperidone formulated to treat the symptoms of schizophrenia and bipolar disorder, and which is in a Phase I clinical trial). Zogenix was founded in 2006 with its headquarter located in San Diego, California.
Since its IPO in 2010, Zogenix stock reached its peak twice, one of them was on Feb 10th 2014 at $4.7. The stock had been experiencing poor performance throughout 2014 despite the fact that its Q3 result outperformed the street's expectation. However, the stock has shown positive signs recently, and it seems to be a good time to enter the market due to its current underprice and several catalysts for growth in 2015.
The November 2014 issue of the Journal of Pain Research published a long-term, open-label study that explained the safety, effectiveness, and tolerability of Zohydro ER.
Further, Zogenix has participated in multiple healthcare conferences that took place in New York City, including the Stifel 2014 Healthcare Conference in November 2014, and the Oppenheimer 25th Annual Healthcare Conference in December 2014.
For the full research report with analyst comments, recommendation and price target on Zogenix Inc. please follow the link. There is no cost obligation required to view analyst report:
ZGNX has not compensated Small Cap IR, BrokerBank Securities, Inc., or Nhung Nguyen, Analyst for the creation or dissemination of this report. Small Cap IR and BrokerBank Securities, Inc., are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap IR and BrokerBank Securities, Inc. do not hold any positions in ZGNX. No liability is accepted by Small Cap IR and BrokerBank Securities, Inc. whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap IR and BrokerBank Securities, Inc. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap IR and BrokerBank Securities, Inc. do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. Small Cap IR is the party responsible for hosting the full analyst report. BrokerBank Securities in the party responsible for issuing the press release and Nhung Nguyen, Analyst, is the author of research report. Small Cap IR has compensated Nhung Nguyen, Analyst two fifty dollars for the right to disseminate this report. BrokerBank Securities has been compensated one hundred dollars to issue press release by Small Cap IR. Information in this report is fact checked and produced on a best efforts basis by Nhung Nguyen, Analyst.
News 
Market Data 
Discover 
